0001179110-20-011996.txt : 20201216
0001179110-20-011996.hdr.sgml : 20201216
20201216163015
ACCESSION NUMBER: 0001179110-20-011996
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201214
FILED AS OF DATE: 20201216
DATE AS OF CHANGE: 20201216
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wright Richard M.
CENTRAL INDEX KEY: 0001646423
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 201392746
MAIL ADDRESS:
STREET 1: C/O CELLDEX THERAPEUTICS, INC.
STREET 2: 53 FRONTAGE ROAD, SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
4
1
edgar.xml
FORM 4 -
X0306
4
2020-12-14
0
0000744218
Celldex Therapeutics, Inc.
CLDX
0001646423
Wright Richard M.
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD, SUITE 220
HAMPTON
NJ
08827
0
1
0
0
Sr. VP & CCO
Common Stock
2020-12-14
4
M
0
11457
9.0165
A
11665
D
Common Stock
2020-12-14
4
S
0
11457
18.6065
D
208
D
Common Stock
2020-12-14
4
M
0
9375
2.78
A
9583
D
Common Stock
2020-12-14
4
S
0
9375
18.6065
D
208
D
Incentive Stock Option
9.0165
2020-12-14
4
M
0
11457
0.00
D
2028-06-13
Common Stock
11457
6876
D
Incentive Stock Option
2.78
2020-12-14
4
M
0
9375
0.00
D
2029-06-19
Common Stock
9375
20625
D
On February 8, 2019, the Company implemented a one-for-fifteen reverse stock split of the Company's issued and outstanding common stock, resulting in the reporting person's ownership of 208 shares of the Company's common stock.
This option was previously reported as covering 275,000 shares at an exercise price of $0.6011 per share, but was adjusted to reflect the reverse stock split that occurred on February 8, 2019.
25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
/s/ Samuel B. Martin, attorney in fact for Richard M. Wright
2020-12-16